TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ribomic, Inc. ( (JP:4591) ) just unveiled an update.
RIBOMIC, Inc. announced positive results from its Phase 2 clinical trial of umedaptanib pegol, an anti-FGF2 aptamer, in pediatric patients with achondroplasia. The trial demonstrated the drug’s efficacy in increasing height growth rates, comparable to the existing treatment Voxzogo®, with no safety concerns. The company plans to advance to a Phase 3 trial, aiming to improve treatment outcomes further and achieve regulatory approval by the end of fiscal year 2028, leveraging its orphan drug designation in Japan.
More about Ribomic, Inc.
RIBOMIC is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics, focusing on innovative treatments for rare diseases.
Average Trading Volume: 2,431,773
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.88B
Find detailed analytics on 4591 stock on TipRanks’ Stock Analysis page.